Search Results - Naidoo, Jarushka

Refine Results
  1. 1
    PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer

    PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer by Shankar, Bairavi, Naidoo, Jarushka

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities

    A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities by Naidoo, Jarushka, Suresh, Karthik

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

    Immunotherapy for Stage III NSCLC: Durvalumab and Beyond by Fitzpatrick, Orla, Naidoo, Jarushka

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Immune-related adverse events and the balancing act of immunotherapy

    Immune-related adverse events and the balancing act of immunotherapy by Conroy, Michael, Naidoo, Jarushka

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Immune-Related Adverse Events: A Case-Based Approach

    Immune-Related Adverse Events: A Case-Based Approach by Connolly, Caoilfhionn, Bambhania, Kalindi, Naidoo, Jarushka

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs

    4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs by Balaji, Aanika, Zhang, Jiajia, Naidoo, Jarushka

    Published 2020
    Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition

    An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition by Naidoo, Jarushka, Dykema, Arbor, D’Alessio, Franco

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Successful Treatment of Scar Pain with Scrambler Therapy

    Successful Treatment of Scar Pain with Scrambler Therapy by Yarchoan, Mark, Naidoo, Jarushka, Smith, Thomas J

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer

    Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer by Wills, Beatriz, Brahmer, Julie R., Naidoo, Jarushka

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    What does the future hold for immunotherapy in cancer?

    What does the future hold for immunotherapy in cancer? by Naidoo, Jarushka, Li, Bob T., Schindler, Katja, Page, David B.

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?

    The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy? by Page, David B, Naidoo, Jarushka, McArthur, Heather L

    Published 2015
    Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities

    Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities by Suresh, Karthik, Naidoo, Jarushka, Lin, Cheng Ting, Danoff, Sonye

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma

    Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma by Rosner, Samuel, Agrawal, Yuri, Sun, Daniel Q, Aygun, Nafi, Schollenberger, Megan D, Lipson, Evan, Naidoo, Jarushka

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  14. 14
    Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses

    Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses by Le, Thomas K., Kaul, Subuhi, Cappelli, Laura C., Naidoo, Jarushka, Semenov, Yevgeniy R., Kwatra, Shawn G.

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  15. 15
    Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

    Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience by Page, David B, Naidoo, Jarushka, Momtaz, Parisa, Bogatch, Kita, Kuk, Deborah, Panageas, Katherine, Yuan, Jianda, Wolchok, Jedd D, Postow, Michael

    Published 2014
    Get full text Get full text
    Text
    Save to List
    Saved in:
  16. 16
    2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors

    2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors by Naidoo, Jarushka, Hu, Chen, Schrek, Karisa, Connolly, Roisin, Santa-Maria, Cesar, Lipson, Evan, Mehra, Ranee, Bettegowda, Redmond, Kristin, Venkatesan, Arun, Grossman, Stuart

    Published 2018
    Get full text Get full text
    Text
    Save to List
    Saved in:
  17. 17
    The cost of cancer care: how far would you go for a trial?

    The cost of cancer care: how far would you go for a trial? by Fitzpatrick, Orla M., Murphy, Catherine, Duignan, Erica, Egan, Keith, Hennessy, Bryan T., Grogan, Liam, Murphy, Adrian, Breathnach, Oscar S., Naidoo, Jarushka, Morris, Patrick G.

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  18. 18
    Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

    Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen by Cappelli, Laura C., Brahmer, Julie R., Forde, Patrick M., Le, Dung T., Lipson, Evan J., Naidoo, Jarushka, Zheng, Lei, Bingham, Clifton O., Shah, Ami A.

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  19. 19
    Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies

    Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies by Chen, Xuguang, Sheikh, Khadija, Nakajima, Erica, Lin, Cheng Ting, Lee, Junghoon, Hu, Chen, Hales, Russell K., Forde, Patrick M., Naidoo, Jarushka, Voong, Khinh Ranh

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  20. 20
    Adaptive neoadjuvant chemotherapy guided by (18)F-FDG-PET in resectable non-small-cell lung cancers: the NEOSCAN trial

    Adaptive neoadjuvant chemotherapy guided by (18)F-FDG-PET in resectable non-small-cell lung cancers: the NEOSCAN trial by Chaft, Jamie E., Dunphy, Mark, Naidoo, Jarushka, Travis, William D., Hellmann, Matthew, Woo, Kaitlin, Downey, Robert, Rusch, Valerie, Ginsberg, Michelle S., Azzoli, Christopher G., Kris, Mark G.

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: